View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Chronic Hepatitis News

SPONSORED CONTENT
Save
SPONSORED CONTENT
January 04, 2023
2 min read
Save

Study highlights 'substantial need' to provide DAA therapy to all patients with HCV

Study highlights 'substantial need' to provide DAA therapy to all patients with HCV

Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.

SPONSORED CONTENT
December 12, 2022
3 min read
Save

D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV

D-LIVR topline results: Lonafarnib all-oral, combination regimens boost response in HDV

Topline findings from the phase 3 D-LIVR trial showed that lonafarnib — boosted with ritonavir and in combination with peginterferon alfa — improved responses in patients with chronic hepatitis D virus, Eiger BioPharmaceuticals announced.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
December 06, 2022
2 min read
Save

Hepatologists’ role in HCV care, elimination ‘remains one of advocacy’

Hepatologists’ role in HCV care, elimination ‘remains one of advocacy’

WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.

SPONSORED CONTENT
December 05, 2022
1 min read
Save

Vosevi effective rescue therapy in patients with chronic HCV after DAA treatment failure

Vosevi effective rescue therapy in patients with chronic HCV after DAA treatment failure

WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.

SPONSORED CONTENT
December 03, 2022
3 min read
Save

The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality

The Liver Meeting: Hepatitis in children, NASH, ‘alarming’ disparities in mortality

The Liver Meeting 2022 delivered the latest research and developments on a variety of topics, including acute hepatitis in children, treatment for hepatitis-related cirrhosis and liver disease mortality during the COVID-19 pandemic.

SPONSORED CONTENT
November 19, 2022
1 min read
Save

Hepatitis B Foundation names Baruch S. Blumberg Prize winner

Hepatitis B Foundation names Baruch S. Blumberg Prize winner

The Hepatitis B Foundation has awarded Stephen Urban, PhD, the 2023 Baruch S. Blumberg Prize for his development of bulevirtide, the first drug approved for the treatment of hepatitis D.

SPONSORED CONTENT
November 18, 2022
2 min read
Save

Recent injection drug use linked to HCV reinfection after DAA treatment

Recent injection drug use linked to HCV reinfection after DAA treatment

WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.

SPONSORED CONTENT
November 17, 2022
2 min read
Save

HCV care must ‘move away from the ivory tower’ to achieve elimination

HCV care must ‘move away from the ivory tower’ to achieve elimination

WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.

SPONSORED CONTENT
November 16, 2022
2 min read
Save

Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050

Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050

WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.

SPONSORED CONTENT
November 15, 2022
2 min read
Save

ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV

ReLink programs led to treatment, engagement in nearly 20% of patients with untreated HCV

WASHINGTON — Implementation of care re-engagement programs led to the treatment of more than 700 patients with untreated hepatitis C virus infection who had been lost to follow-up, according to research presented at The Liver Meeting.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails